Novel biomarkers for contrast-induced acute kidney injury

Carlo Briguori, Cristina Quintavalle, Elvira Donnarumma, Gerolama Condorelli

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Biomarkers of acute kidney injury (AKI) may be classified in 2 groups: (1) those representing changes in renal function (e.g., serum creatinine or cystatin C and urine flow rate) and (2) those reflecting kidney damage (e.g., kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18, etc.). According to these 2 fundamental criteria, 4 subgroups have been proposed: (1) no marker change; (2) damage alone; (3) functional change alone; and (4) combined damage and functional change. Therefore, a new category of patients with "subclinical AKI" (that is, an increase in damage markers alone without simultaneous loss of kidney function) has been identified. This condition has been associated with higher risk of adverse outcomes (including renal replacement therapy and mortality) at followup. The ability to measure these physiological variables may lead to identification of patients at risk for AKI and early diagnosis of AKI and may lead to variables, which may inform therapeutic decisions.

Original languageEnglish
Article number568738
JournalBioMed Research International
Volume2014
DOIs
Publication statusPublished - 2014

Fingerprint

Biomarkers
Acute Kidney Injury
Lipocalins
Kidney
Cystatin C
Gelatinases
Interleukin-18
Creatinine
Flow rate
Molecules
Renal Replacement Therapy
Early Diagnosis
Urine
Mortality
Wounds and Injuries
Serum
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Briguori, C., Quintavalle, C., Donnarumma, E., & Condorelli, G. (2014). Novel biomarkers for contrast-induced acute kidney injury. BioMed Research International, 2014, [568738]. https://doi.org/10.1155/2014/568738

Novel biomarkers for contrast-induced acute kidney injury. / Briguori, Carlo; Quintavalle, Cristina; Donnarumma, Elvira; Condorelli, Gerolama.

In: BioMed Research International, Vol. 2014, 568738, 2014.

Research output: Contribution to journalArticle

Briguori, C, Quintavalle, C, Donnarumma, E & Condorelli, G 2014, 'Novel biomarkers for contrast-induced acute kidney injury', BioMed Research International, vol. 2014, 568738. https://doi.org/10.1155/2014/568738
Briguori, Carlo ; Quintavalle, Cristina ; Donnarumma, Elvira ; Condorelli, Gerolama. / Novel biomarkers for contrast-induced acute kidney injury. In: BioMed Research International. 2014 ; Vol. 2014.
@article{1359e3f4732c4b1c9da41fad0e7c7fca,
title = "Novel biomarkers for contrast-induced acute kidney injury",
abstract = "Biomarkers of acute kidney injury (AKI) may be classified in 2 groups: (1) those representing changes in renal function (e.g., serum creatinine or cystatin C and urine flow rate) and (2) those reflecting kidney damage (e.g., kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18, etc.). According to these 2 fundamental criteria, 4 subgroups have been proposed: (1) no marker change; (2) damage alone; (3) functional change alone; and (4) combined damage and functional change. Therefore, a new category of patients with {"}subclinical AKI{"} (that is, an increase in damage markers alone without simultaneous loss of kidney function) has been identified. This condition has been associated with higher risk of adverse outcomes (including renal replacement therapy and mortality) at followup. The ability to measure these physiological variables may lead to identification of patients at risk for AKI and early diagnosis of AKI and may lead to variables, which may inform therapeutic decisions.",
author = "Carlo Briguori and Cristina Quintavalle and Elvira Donnarumma and Gerolama Condorelli",
year = "2014",
doi = "10.1155/2014/568738",
language = "English",
volume = "2014",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Novel biomarkers for contrast-induced acute kidney injury

AU - Briguori, Carlo

AU - Quintavalle, Cristina

AU - Donnarumma, Elvira

AU - Condorelli, Gerolama

PY - 2014

Y1 - 2014

N2 - Biomarkers of acute kidney injury (AKI) may be classified in 2 groups: (1) those representing changes in renal function (e.g., serum creatinine or cystatin C and urine flow rate) and (2) those reflecting kidney damage (e.g., kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18, etc.). According to these 2 fundamental criteria, 4 subgroups have been proposed: (1) no marker change; (2) damage alone; (3) functional change alone; and (4) combined damage and functional change. Therefore, a new category of patients with "subclinical AKI" (that is, an increase in damage markers alone without simultaneous loss of kidney function) has been identified. This condition has been associated with higher risk of adverse outcomes (including renal replacement therapy and mortality) at followup. The ability to measure these physiological variables may lead to identification of patients at risk for AKI and early diagnosis of AKI and may lead to variables, which may inform therapeutic decisions.

AB - Biomarkers of acute kidney injury (AKI) may be classified in 2 groups: (1) those representing changes in renal function (e.g., serum creatinine or cystatin C and urine flow rate) and (2) those reflecting kidney damage (e.g., kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18, etc.). According to these 2 fundamental criteria, 4 subgroups have been proposed: (1) no marker change; (2) damage alone; (3) functional change alone; and (4) combined damage and functional change. Therefore, a new category of patients with "subclinical AKI" (that is, an increase in damage markers alone without simultaneous loss of kidney function) has been identified. This condition has been associated with higher risk of adverse outcomes (including renal replacement therapy and mortality) at followup. The ability to measure these physiological variables may lead to identification of patients at risk for AKI and early diagnosis of AKI and may lead to variables, which may inform therapeutic decisions.

UR - http://www.scopus.com/inward/record.url?scp=84902166306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902166306&partnerID=8YFLogxK

U2 - 10.1155/2014/568738

DO - 10.1155/2014/568738

M3 - Article

VL - 2014

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 568738

ER -